This article relies largely or entirely on a single source. Relevant discussion may be found on the talk page. Please help improve this articlebyintroducing citations to additional sources.
Find sources: "Methylenedioxyallylamphetamine" – news · newspapers · books · scholar · JSTOR (October 2017) |
Methylenedioxyallylamphetamine (MDALor3,4-methylenedioxy-N-allylamphetamine) is a lesser-known psychedelic drug. It is also the N-allyl derivativeof3,4-methylenedioxyamphetamine (MDA). MDAL was first synthesized by Alexander Shulgin. In his book PiHKAL, the minimum dosage is listed as 180 mg, and the duration unknown.[1] MDAL produces few to no effects on its own, but may enhance the effects of LSD. Very little data exists about the pharmacological properties, metabolism, and toxicity of MDAL.
| |
| Names | |
|---|---|
| Preferred IUPAC name
N-[1-(2H-1,3-Benzodioxol-5-yl)propan-2-yl]prop-2-en-1-amine | |
| Identifiers | |
3D model (JSmol) |
|
| ChemSpider |
|
PubChem CID |
|
| UNII | |
CompTox Dashboard (EPA) |
|
| |
| |
| Properties | |
| C13H17NO2 | |
| Molar mass | 219.284 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.[2]
 | This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it. |
